Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in pediatric obesity (6-11 years)
NCT05696847Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2023
- Primary completion
- Jan 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tirzepatide in obesity (6 cohorts), sponsored by Eli Lilly and Company. Primary endpoints: Treatment Emergent Adverse Events and Serious Adverse Events. Started Feb 2023; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05696847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05696847.